.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The ADAPT phase 3 trial evaluated efgartigimod, an engineered Fc-fragment that blocks the neonatal Fc receptor and reduces circulating pathogenic IgG. Adults with generalized myasthenia gravis received efgartigimod or placebo in repeated treatment cycles. Among acetylcholine-receptor antibody-positive participants, a substantially larger proportion achieved the prespecified MG-ADL responder outcome with efgartigimod during the first cycle. The treatment was generally well tolerated, with headache and nasopharyngitis among the more common adverse events. The study is important because it demonstrated that modulating IgG recycling can translate into rapid clinical improvement in a broad MG population. For HCPs, efgartigimod provides a targeted treatment option for patients whose generalized symptoms remain burdensome despite background therapy. Clinical response should guide the interval between treatment cycles rather than assuming a fixed schedule for every patient. The trial also reinforces the value of measuring patient-centred outcomes such as activities of daily living in addition to muscle strength. The findings directly complement IANCON's focus on practical pharmacotherapy and advanced treatment options for myasthenia gravis.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ADAPT phase 3 trial evaluated efgartigimod, an engineered Fc-fragment that blocks the neonatal Fc receptor and reduces circulating pathogenic IgG. Adults with generalized myasthenia gravis received efgartigimod or placebo in repeated treatment cycles. Among acetylcholine-receptor antibody-positive participants, a substantially larger proportion achieved the prespecified MG-ADL responder outcome with efgartigimod during the first cycle. The treatment was generally well tolerated, with headache and nasopharyngitis among the more common adverse events. The study is important because it demonstrated that modulating IgG recycling can translate into rapid clinical improvement in a broad MG population. For HCPs, efgartigimod provides a targeted treatment option for patients whose generalized symptoms remain burdensome despite background therapy. Clinical response should guide the interval between treatment cycles rather than assuming a fixed schedule for every patient. The trial also reinforces the value of measuring patient-centred outcomes such as activities of daily living in addition to muscle strength. The findings directly complement IANCON's focus on practical pharmacotherapy and advanced treatment options for myasthenia gravis.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
